Vandemaele Fréderic, Bleyen Nele, Abuaboud Omran, vanderMeer Ed, Jacobs Anton, Goddeeris Bruno M
Laboratory of Livestock Physiology and Immunology, Faculty of Bioscience Engineering, Catholic University Leuven, Kasteelpark Arenberg 30, 3001, Leuven, Belgium.
Avian Pathol. 2006 Jun;35(3):238-49. doi: 10.1080/03079450600710997.
The aim of this study was to investigate whether immunization with the sugar binding domain of PapGII (PapGII196) was able to protect chickens against avian pathogenic Escherichia coli. PapGII196 was expressed, purified by Ni-NTA column chromatography and shown to retain its biological activity, as demonstrated by binding to its receptor, globoside. PapGII196 was tested as a vaccine in specific pathogen free broilers and also by vaccinating breeders and assessing protection in their offspring, and using aerosol exposure or air sac inoculation for challenge. Notwithstanding a strong anti-PapGII196 serum IgG response in vaccinated birds in all experiments and inhibition of haemagglutination by serum from PapGII196-vaccinated birds, chickens were not protected against avian pathogenic E. coli. These findings suggest that PapGII may not be a useful candidate for inclusion in vaccines against avian pathogenic E. coli.
本研究的目的是调查用PapGII的糖结合结构域(PapGII196)进行免疫是否能够保护鸡抵御禽致病性大肠杆菌。PapGII196得到表达,通过镍-氮三乙酸柱色谱法进行纯化,并显示保留其生物活性,这通过与它的受体红细胞糖苷脂结合得以证明。PapGII196作为疫苗在无特定病原体肉鸡中进行了测试,也通过给种鸡接种疫苗并评估其后代的保护情况,以及采用气溶胶暴露或气囊接种进行攻毒。尽管在所有实验中接种疫苗的鸡产生了强烈的抗PapGII196血清IgG反应,并且PapGII196疫苗接种鸡的血清抑制了血凝,但鸡并未受到保护以抵御禽致病性大肠杆菌。这些发现表明,PapGII可能不是用于抗禽致病性大肠杆菌疫苗中的有用候选物。